Looking For New Technologies To Address Solubility Challenges By Michiel Van Speybroeck Ph.D., R&D Director, Formac Pharmaceuticals
It is estimated that around 70% to 90% of new chemical entities in discovery pipelines and 40% of drugs on the market are poorly soluble in water. Poor aqueous solubility may drastically limit oral bioavailability and ultimately compromise therapeutic outcome. It is becoming increasingly apparent that the adsorption of poorly water soluble drugs on mesoporous silica materials is a very effective way to address this solubility problem.
Magnetic Capture-Based SERS Immunoassays By Mark H. Harpster, Jing Neng, Patrick A. Johnson, and Rick Cox, University of Wyoming and Delta Nu Intevac
Understand and apply magnetic capture-based SERS immunoassays for multiplexed antigen detection with this technical information on handheld Raman spectroscopy with a practical user interface for rapid operation procedures and material/chemical identification.
Johns Hopkins' Advanced Biotechnology Studies (ABS) Program is rooted in the multidisciplinary skills of basic research, drug discovery technologies, bioinformatics, regulatory science, and product commercialization that the industry demands. Join us to learn more about the programs and the admissions requirements. Join us in an online discussion and chat about the program with faculty and the advisors.
IBC's Flexible Facilities conference (April 2 to 4, in San Francisco) brings together senior-level VPs, directors, managers, and group leaders to discuss the strategic, technical, economic, regulatory, and quality considerations necessary for implementation of more flexible, modular, multi-product biomanufacturing facilities throughout the world. Download the brochure today at: http://bit.ly/VSEkXF